clinic
trial
gene
therapi
cystic
fibrosi
suggest
current
level
gene
transfer
effici
probabl
low
result
clinic
benefit
larg
result
barrier
face
gene
transfer
vector
within
airway
respiratori
epithelium
evolv
complex
seri
extracellular
barrier
mucu
lack
receptor
immun
surveil
etc
aim
prevent
penetr
lumen
deliv
materi
includ
gene
therapi
vector
addit
cell
hurdl
overcom
includ
dna
degrad
nuclear
import
abil
maintain
longterm
transgen
express
strategi
overcom
barrier
address
review
includ
use
clinic
relev
adjunct
overcom
extraand
intracellular
barrier
ii
lessconvent
deliveri
rout
intraven
utero
administr
iii
effici
nonvir
vector
stealth
virus
readminist
iv
new
approach
prolong
transgen
express
mean
altern
promot
integr
vector
advanc
potenti
improv
effici
gene
deliveri
airway
epithelium
thu
make
gene
therapi
realist
option
cystic
fibrosi
clearli
urgent
need
novel
therapeut
approach
cystic
fibrosi
cf
common
recespreclin
studi
carri
soon
sive
inherit
lethal
diseas
among
caucasian
isol
gene
show
viral
popul
affect
approxim
one
nonvir
gene
transfer
agent
gta
abl
newborn
cf
caus
mutat
cystic
correct
chlorid
ion
transport
defect
cf
fibrosi
transmembran
conduct
regul
transgen
mice
success
studi
led
cftr
gene
date
around
differ
sever
group
initi
clinic
trial
gene
mutat
identifi
underli
gene
transfer
cf
patient
three
class
gta
mutat
lead
defect
product
cftr
use
far
adenoviru
adenoassoci
protein
campregul
chlorid
cl
channel
viru
aav
cation
lipid
although
lung
locat
apic
membran
epitheli
cell
remain
medic
relev
target
mani
although
organ
affect
cf
also
includ
investig
chose
start
clinic
studi
pancrea
gut
liver
reproduct
tract
clinilook
gene
transfer
nasal
mucosa
nasal
cal
pictur
domin
pulmonari
diseas
airway
epithelia
similar
histolog
recurr
cycl
infect
lead
inflamm
cfassoci
abnorm
ion
transport
bronchiectasi
greater
patient
pulmonari
epithelia
compar
lung
nasal
death
respiratori
failur
isol
caviti
easier
access
gene
transfer
gene
respons
cf
suggest
safeti
measur
repres
reduc
risk
feasibl
new
therapeut
treatment
base
patient
case
occurr
side
effect
cftr
gene
transfer
patient
cf
nine
clinic
trial
use
recombin
adenoviru
rational
develop
gene
therapi
protoa
gta
publish
far
five
col
reli
fact
heterozygot
appear
involv
administr
viru
lung
phenotyp
normal
express
cftr
low
epithelium
result
report
dysfunct
epitheli
line
cell
alway
consist
nose
assess
affect
organ
lung
access
follow
singl
applic
approxim
onenoninvas
techniqu
furthermor
although
conthird
show
chang
chlorid
transport
vention
treatment
increas
life
expect
function
measur
assess
lung
cf
patient
approxim
year
studi
although
evid
vectorderiv
cftr
mrna
found
common
find
differ
cf
subject
importantli
studi
publish
includ
dosedepend
gener
accept
effici
vivo
mild
local
inflamm
ii
progress
lack
gene
transfer
current
avail
vector
need
express
follow
repeat
administr
increas
review
progress
two
phase
singl
administr
dose
escal
made
improv
gta
hurdl
effici
trial
use
aav
gta
report
far
transgen
express
vector
overaavcftr
deliv
maxillari
sinu
come
enter
airway
epitheli
cell
nebulis
lung
cf
subject
case
aav
deliveri
shown
safe
vector
dna
found
pcr
day
extracellular
barrier
maxillari
sinus
day
airway
deliv
maxillari
sinu
respiratori
epithelium
present
particular
degre
dosedepend
chlorid
transport
correcchalleng
gta
sinc
one
function
upper
tion
observ
howev
studi
respiratori
tract
keep
foreign
particl
vectorderiv
mrna
detect
lung
airway
epithelia
evolv
complex
cation
lipid
use
eight
clinic
seri
barrier
prevent
penetr
lumen
trial
two
involv
nebulisadeliv
materi
includ
viral
nontion
lipoplex
lower
airway
viral
gta
cell
interstiti
compart
differ
lipoplex
use
includ
dccholthes
barrier
consist
welldefin
mucu
dope
dotap
layer
may
bind
inhal
vector
remov
edmpccholesterol
dna
dose
via
mucu
clearanc
mechan
ii
glycocalyx
rang
mg
mg
administ
may
bind
vector
prevent
bind
cell
nose
mg
nebulis
surfac
receptor
perhap
importantli
lung
result
similar
report
iii
apic
cell
membran
rel
devoid
adenovir
vector
correct
toward
viral
receptor
growth
tropic
receptor
fig
normal
valu
chlorid
defect
observ
seri
barrier
complement
nose
epitheli
tight
junction
moder
leaki
lung
last
day
week
ion
quit
tight
larger
solut
therebi
interestingli
one
studi
nake
dna
prevent
penetr
current
vector
report
effici
lipoplex
unlik
lumen
surfac
interstitium
addit
virus
report
lipoplex
cf
lung
characteris
presenc
success
readminist
without
appar
loss
discontinu
barrier
purul
secret
efficaci
howev
mild
flulik
symptom
contain
exogen
actin
dna
inflammatori
note
lung
trial
follow
aerosolis
product
modifi
integr
lipoplex
liposomedna
complex
probabl
relat
limit
gene
deliveri
airway
cf
sputum
presenc
unmethyl
cpg
motif
shown
retard
movement
particl
bacteri
deriv
plasmid
dna
size
compar
lipoplex
summari
within
year
clone
almost
complet
block
particl
cftr
gene
tremend
progress
made
furthermor
bind
neg
charg
cf
proofofprincipl
correct
basic
chlorid
mucu
compon
gene
complex
may
defect
establish
within
target
organ
chang
surfac
charg
size
result
vivo
cf
subject
howev
none
clinic
decreas
transport
lipoplex
trial
cite
sodium
hyperabsorpt
alter
mucu
therefor
decreas
cellular
uptak
three
gta
use
achiev
limit
success
none
outshin
other
interestingus
ex
vivo
sheep
trachea
model
demonli
despit
nonvir
vector
arguabl
less
strate
cation
lipidmedi
gene
transfer
effici
virus
anim
model
laboranot
adenovir
vector
recombin
sendai
viru
tori
studi
clinic
trial
shown
might
inhibit
normal
mucu
remov
extracellular
barrier
includ
presenc
infect
mucu
sputum
mucociliari
clearanc
tight
junction
cell
limit
access
viral
vector
receptor
localis
basolater
membran
altern
gene
transfer
agent
could
deliv
intraven
v
rout
even
unlik
airway
epitheli
cell
target
inflamm
ctlmediat
degrad
transduc
cell
neutral
antibodi
limit
transgen
express
readministr
gene
transfer
vector
hidden
stem
progenitor
cell
could
target
lentivir
vector
insid
cell
genet
materi
overcom
endosom
cytoplasm
degrad
get
nucleu
ce
ciliat
cell
b
basal
cell
g
goblet
cell
tj
tight
junction
c
capillari
smg
submucos
gland
layer
significantli
increas
transgen
exnant
human
dnase
shown
reduc
sputum
pression
similar
result
obtain
viscoelast
facilit
transport
nanospher
cation
polym
pei
use
howev
though
cf
sputum
mix
recent
shown
mucu
barrier
lipoplex
polyplex
alter
abil
part
overcom
treatment
mucolyt
mediat
gene
deliveri
agent
nacystelyn
either
cation
recent
find
suggest
glycocalyx
lipid
edmpc
chol
cation
polym
may
also
repres
anoth
major
obstacl
gene
pei
use
deliv
gene
airway
epithelium
transfer
airway
epithelium
glycocalyx
compos
mani
carbohydratebear
structur
similarli
sputum
bronchoalveolar
lavag
includ
glycoprotein
glycolipid
proteoglyfluid
balf
recov
cf
patient
can
treatment
agent
remov
compon
shown
inhibit
liposom
adenoviru
glycocalyx
neuroaminidas
aavmedi
gene
transfer
effici
shown
enhanc
suscept
polaris
cell
howev
cf
sputum
treat
recomto
transduct
ad
aav
vector
binant
human
dnase
increas
liposomemeattempt
made
circumv
barrier
diat
gene
deliveri
observ
recombith
mucos
surfac
deliv
transgen
via
bloodstream
intraven
rout
may
make
cell
surfac
barrier
possibl
access
basolater
membran
airway
epitheli
cell
characteris
higher
rate
earli
studi
model
system
emof
endocytosi
increas
densiti
viral
ploy
poorli
differenti
airway
epitheli
cell
receptor
howev
difficulti
overcom
suggest
gene
transfer
effici
varieti
larg
number
barrier
vascular
vector
would
high
howev
advent
compart
airway
epitheli
cell
endotheli
welldifferenti
cultur
system
becam
clear
cell
endotheli
cell
basement
membran
interthat
airway
lumenfac
columnar
cell
stitium
epitheli
basement
membran
make
predomin
cell
type
must
transduc
rout
challeng
larg
number
studi
vivo
rel
resist
viral
nonvir
gene
conduct
identifi
cell
lung
transfer
ii
apic
surfac
welldifferenar
transduc
intraven
iv
inject
tiat
airway
epitheli
cell
low
basal
liposomedna
complex
stimul
rate
endocytosi
contrast
current
conclud
major
cell
transfect
avail
cell
cultur
compos
basal
pulmonari
endotheli
cell
poorli
differenti
cell
highli
transducstudi
report
transfect
type
ii
alveolar
ibl
mirror
airway
lumen
vivo
epitheli
cell
studi
report
airway
epitheli
cell
transfect
iv
synthet
viral
vector
unabl
inject
cation
lipiddna
complex
decreas
progress
cell
becam
may
due
properti
specif
polaris
differenti
similar
report
formul
longer
circul
time
sinc
demonstr
much
reduct
gene
similar
result
obtain
gta
deliveri
due
decreas
bind
dotapdop
dccholdop
cation
lipid
surfac
matur
airway
epiand
kda
pei
administ
thelial
cell
also
declin
rate
independ
rout
administr
internalis
bound
complex
innat
immun
defenc
mechan
preexist
cell
hypothesi
reduct
bind
immun
like
play
crucial
role
defendmay
due
differ
surfac
charg
ing
lung
foreign
particl
includ
gene
poorli
welldifferenti
cell
poorli
therapi
materi
airway
macrophag
known
differenti
cell
exhibit
receptormedi
endoreduc
amount
gta
abl
reach
epithelicytosi
pinocytosi
phagocytosi
welldifferen
cell
either
via
direct
mechan
phagocytosi
tiat
cell
capabl
receptormedi
sinc
antigen
present
cell
endocytosi
report
indic
stimul
host
immun
system
preexist
cell
prolifer
may
influenc
cation
lipidmeimmun
antibodi
wildtyp
virus
diat
transfect
activ
either
make
epia
adenoviru
aav
could
hinder
abil
thelial
cell
suscept
transfectarget
epitheli
cell
effici
survey
normal
tion
temporari
disrupt
tight
junction
cf
subject
shown
virtual
subject
would
allow
lipoplex
either
access
antibodi
two
basolater
surfac
welldifferenti
cell
use
viral
vector
far
although
access
immatur
less
differenti
cell
respect
neutralis
antibodi
regard
viral
vector
demonalso
observ
individu
higher
strate
receptor
adenoviru
baselin
antiad
neutralis
antibodi
titr
mount
retroviru
localis
basolater
higher
neutralis
antibodi
respons
vector
membran
therefor
access
administr
vector
deliv
topic
first
exampl
report
purinoreceptor
highli
express
apic
surfac
principl
four
gener
strategi
may
improv
epitheli
cell
stimul
internalis
upon
gene
transfer
effici
airway
epithelia
utp
activ
increas
gene
transfer
effici
observ
adenovir
vector
tight
junction
conjug
biotinyl
utp
ligand
use
barrier
function
epitheli
tight
junction
target
endogen
purinoreceptor
transient
disrupt
vector
differenti
human
airway
epitheli
cell
known
access
basolater
membran
target
cell
refractori
adenovirusmedi
gene
transfer
rich
viral
receptor
higher
similar
result
obtain
gta
rate
endocytosi
achiev
use
retarget
bind
bradykinin
receptor
ca
chelat
agent
egta
nonurokinas
plasminogen
activ
receptor
ionic
deterg
polidocanol
serpin
enzym
complex
receptor
secr
antibodi
abl
block
function
protein
express
apic
surfac
airway
involv
tight
junctioncomplex
eepitheli
cell
administr
plasmid
dna
cadherin
addit
mediumchain
fatti
acid
carri
cftr
cdna
condens
polylsuch
sodium
caprat
shown
lysin
secr
ligand
cf
mice
produc
correct
better
agent
enhanc
gene
transfer
cl
efflux
normal
sodium
channel
egta
via
disrupt
major
structur
activ
revers
nitric
oxid
compon
tight
junction
croyl
et
al
downregul
recent
found
blend
sucros
mannitol
investig
current
tri
characteris
pluron
enhanc
adenoviralmedi
gene
new
ligand
target
receptor
present
apic
express
larg
small
lung
airway
surfac
airway
epithelia
one
method
use
formul
shown
increas
tight
junction
phage
display
librari
screen
peptid
bind
permeabl
allow
use
log
lower
viral
high
affin
airway
epitheli
cell
dose
airway
instil
perfluorochem
mainli
done
vitro
sever
promis
pfc
liquid
also
transient
open
tight
junccandid
alreadi
identifi
tion
enhanc
adenovir
aav
attempt
identifi
relev
molecul
cation
lipidmedi
gene
transfer
although
vivo
biopan
current
evalu
procedur
increas
inflamm
attract
altern
strategi
evalu
systemat
glycoprotein
envelop
modif
host
virus
abil
effici
infect
airway
apic
membran
modifi
epithelia
use
glycoprotein
pseudobind
vector
one
approach
incorpor
type
recombin
viral
vector
virus
unnatur
sugar
membran
glycoprotein
alreadi
shown
infect
polaris
airway
use
molecular
handl
novel
epithelium
apic
surfac
includ
respirareceptor
construct
artifici
receptor
entori
pathogen
human
coronaviru
hanc
adenovir
bind
gene
transfer
cell
influenza
viru
normal
rel
resist
adenoviru
strain
virus
filovirida
famili
infect
suggest
feasibl
gene
marburg
ebola
viru
use
transfer
strategi
biosynthet
machineri
ebolapseudotyp
hiv
vector
kobing
et
al
cell
use
engin
novel
receptor
show
effici
stabl
transduct
intact
cell
surfac
airway
epithelium
apic
surfac
vivo
modif
vector
also
nonth
gta
modifi
order
target
specif
given
low
densiti
adreceptor
receptor
apic
membran
capacith
apic
membran
sever
strategi
increas
ty
bind
internalis
vector
one
cell
bind
via
nonfibredepend
pathway
develop
complex
ad
vector
polyus
fusogen
lipid
peptid
gala
cation
incorpor
ad
calcium
phosand
influenza
haemagglutinin
disrupt
phate
precipit
shown
enhanc
endosom
membran
neutral
lipid
dioleoylgen
transfer
airway
epithelia
vitro
vivo
phosphatidylethanolamin
dope
gener
emthes
strategi
thought
neutralis
advers
ploy
fusogen
helper
lipid
cation
charg
interact
neg
charg
ad
lipiddna
complex
second
approach
involv
particl
neg
charg
cell
surfac
use
dna
deliveri
system
high
buffer
result
improv
bind
uptak
ad
capac
flexibl
swell
proton
vector
rational
endosom
ruptur
furthermor
report
synph
drop
late
endosom
inhibit
thetic
viral
vector
mediat
gene
buffer
capac
formul
led
use
transfer
differenti
airway
epithelia
phsensit
liposom
polyethylenimin
increas
prolong
contact
time
gene
transfer
agent
great
number
secondari
amin
pei
behav
identif
new
viral
vector
proton
spong
abl
buffer
low
ph
improv
bind
entri
apic
endosom
result
inhibit
low
surfac
report
new
viral
phactiv
nucleas
lead
larg
increas
vector
new
serotyp
exist
vector
ionic
concentr
insid
endosom
recent
shown
contrast
aav
aav
final
result
osmot
swell
due
water
serotyp
abl
infect
human
airway
epithelia
entri
ruptur
organel
lumen
surfac
suggest
contrast
plasmid
dna
viral
vector
sialic
acid
either
receptor
aav
evolv
mechan
escap
endosom
degradanecessari
compon
receptor
complex
tion
prerequisit
recombin
sendai
viru
singlestrand
rna
subsequ
nuclear
localis
virion
hanparamyxoviru
also
abl
infect
airway
epithelisen
et
al
shown
passag
al
cell
lumen
surfac
envelop
endosom
acid
compon
expos
aav
conprotein
f
fusion
hn
haemagglutinin
dition
modifi
capsid
allow
viru
shown
interact
cholesterol
sialic
use
cytoskeleton
subsequ
traffick
event
acid
respect
molecul
known
nucleu
sendai
viru
use
f
protein
present
apic
membran
airway
epitheli
fuse
envelop
cell
plasma
membran
cell
similarli
recombin
respiratori
allow
genet
materi
releas
directli
syncyti
viru
recent
develop
cytoplasm
thu
avoid
endosom
abil
infect
ciliat
cell
via
lumen
degrad
led
use
hvjliposom
membran
new
gene
transfer
agent
uvinactiv
sev
particl
mix
togeth
lipid
liposom
formul
order
allow
plasmid
intracellular
barrier
dna
introduc
cytoplasm
transfect
cell
viral
nonvir
vector
enter
cell
endocytosi
normal
process
internalis
cytoplasmbas
degrad
pathway
degrad
extracellular
materi
viral
vector
synthet
vector
endosom
pei
hvjliposom
characteris
abil
escap
endosom
degrad
howev
plasmidbas
vector
quit
suscept
releas
cytoplasm
enter
endosom
degrad
attempt
made
nucleu
hurdl
encount
synthet
enhanc
transgen
escap
endosomevectorbas
strategi
characteris
low
gene
lysosom
pathway
fig
one
approach
involv
transfer
effici
plasmid
dna
quickli
degrad
ca
sensit
cytosol
nucleas
sever
approach
taken
improv
appar
halflif
min
duan
et
nuclear
entri
pdna
includ
electrostat
al
show
polaris
epitheli
cell
aav
bind
pdna
nlscontain
protein
capsid
ubiquin
endocytosi
coval
attach
nlsprocess
barrier
raav
transduct
motif
doublestrand
dna
regard
proteasomedepend
degrad
ubiquin
latest
approach
studi
publish
far
molecul
repres
major
pathway
dispos
use
nl
simian
viru
endogen
foreign
protein
vivo
applilarg
antigen
traffick
nucleu
cation
proteasom
inhibitor
mous
lung
well
characteris
also
shown
mediat
augment
raavmedi
gene
transfer
undenuclear
import
nonkaryophil
protein
use
tectabl
level
mean
piggyback
approach
sebestyen
et
al
demonepitheli
cell
larg
bronchiol
strate
nuclear
accumul
digitoninpermeabilis
cell
fail
show
uptak
modifi
nuclear
import
dna
nuclei
intact
cell
suggest
coval
modif
pdna
signal
peptid
within
cytoplasm
transgen
must
may
alter
behaviour
interact
import
nucleu
transcrib
cellular
factor
cap
luciferas
gene
plasmidbas
express
nuclear
import
ratewith
singl
nl
peptid
zanta
et
al
show
limit
step
intracellular
traffick
pdna
increas
gene
transfer
effici
either
nake
complex
synthet
vector
howev
major
drawback
techniqu
larg
uncharacteris
fig
nonvir
rel
low
amount
nlspdna
gene
transfer
entri
exogen
dna
produc
nucleu
occur
cell
activ
divid
develop
peptid
nucleic
acid
pna
ing
ie
nuclear
envelop
break
oligonucleotid
analogu
sugar
phosthi
consist
observ
wellphat
backbon
nucleic
acid
replac
differenti
nondivid
airway
epitheli
cell
synthet
peptid
backbon
led
show
low
transfect
effici
pollard
et
al
develop
field
pna
capabl
show
less
nake
cdna
copi
sequencespecif
recognit
dna
rna
microinject
cytoplasm
effect
follow
watsoncrick
hydrogenbond
traffick
nucleu
scheme
use
link
peptid
result
may
larg
due
inabl
nlsmotif
plasmid
dna
advantag
pdna
effect
transloc
nuclear
strategi
nl
peptid
pore
complex
npc
npc
compris
link
specif
region
plasmid
dna
larg
famili
protein
nucleoporin
form
effect
transcript
gene
locat
structur
central
channel
surround
elsewher
plasmid
furthermor
precis
eight
peripher
channel
thought
number
nlsmotif
attach
larg
peripher
channel
nm
diamet
allow
quantiti
modifi
pdna
obtain
small
solut
protein
kda
freeli
howev
none
strategi
describ
diffus
nucleu
larger
protein
need
use
enhanc
nuclear
import
gene
nuclear
localis
signal
nl
order
transfer
express
airway
epitheli
cell
vivo
activ
transport
central
channel
addit
report
suggest
pore
physiolog
condit
supersom
polyc
pei
lactosyl
coil
pdna
diamet
nm
larger
polyllysin
may
facilit
nuclear
uptak
relax
conform
thu
suggest
passiv
pdna
unlik
lipoplex
complex
diffus
pdna
npc
highli
remain
intact
nuclear
transloc
unlik
therefor
target
pdna
might
suggest
exist
nuclear
import
pathnuclear
shuttl
protein
becom
part
way
distinct
convent
nl
one
design
gta
develop
transfer
nondivid
unlik
plasmidbas
approach
viral
vector
cell
cf
gene
therapi
evolv
effici
way
enter
nucleu
cytoplasm
movement
viral
dna
toward
direct
adenovir
capsid
protein
present
nucleu
facilit
interact
viral
vector
deliveri
result
product
neuprotein
polymeras
capsid
protein
tralis
antibodi
nab
limit
repeat
vector
microtubular
network
recent
administr
shown
adenoviru
type
dock
sever
approach
taken
reduc
protein
nuclear
pore
hijack
expressionlimit
immun
respons
recipi
histon
specif
receptor
effect
virusbas
gene
therapi
target
uncoat
nucleocapsid
immunosuppress
drug
cyclophosnuclear
pore
consequ
viral
dna
liberphamid
cyclosporin
reat
near
open
pore
posit
port
prolong
transgen
express
facilit
transloc
nucleu
repeat
gene
transfer
lung
howev
viral
vector
retrovirus
potenti
induc
sever
system
side
effect
may
nuclear
import
depend
mitot
statu
limit
clinic
applic
drug
furtherof
cell
recent
report
prolong
gener
immunosuppress
cf
polypurin
tract
cppt
present
genom
patient
lung
colonis
pathogen
lead
format
triplestrand
dna
bacteria
could
injuri
structur
flap
recognis
ii
topic
corticosteroid
budesonid
nuclear
import
machineri
host
cell
allow
success
readministr
adenoultim
result
transport
viru
least
twice
compar
salinetr
genom
nucleu
across
nuclear
pore
anim
budesonid
treatment
result
significomplex
introduct
cppt
sequenc
cantli
higher
transgen
express
lower
recombin
lentivir
vector
shown
amount
nab
balf
serum
howenh
nuclear
import
therefor
transgen
ever
differ
disappear
five
previexpress
virus
sendai
ou
exposur
viru
viru
nuclear
import
ratelimit
step
sinc
iii
coadministr
interferong
ifng
replic
transcript
occur
shown
diminish
plasm
activ
cell
format
nab
allow
effici
readministr
least
recombin
viru
potenti
drawback
host
immun
respons
approach
cell
inhibit
expens
increas
activ
thu
transgen
express
transient
unless
g
capabl
inhibit
humor
lungresid
stem
cell
target
treatment
immun
might
enhanc
elimin
adenocf
gene
therapi
requir
repeat
administravirustransduc
cell
ctl
tion
throughout
lifetim
patient
iv
ctl
b
cell
respons
requir
prevent
activ
humor
cellular
imb
overcom
order
readminist
vector
mune
respons
virus
thu
caus
prolong
includ
antigennonspecif
cytokinetransgen
express
effici
readministr
depend
respons
result
acut
inflamm
sever
strategi
adopt
includ
ii
cytotox
tlymphocyt
ctl
depenus
nondeplet
monoclon
antibodi
dent
respons
direct
cell
express
viral
molecul
blockad
either
protein
result
chronic
inflamm
ligand
lack
persist
transgen
express
iii
costimulatori
signal
necessari
complet
helper
lymphocytedepend
respons
tcell
activ
treatment
result
suppress
cellular
humor
respons
proshorten
version
cftr
gene
minigen
long
transgen
express
case
anoth
approach
expand
raav
packag
vector
readministr
four
time
howcapac
transsplic
overlap
vector
ever
nonhuman
primat
treatment
anti
first
reconstitut
gene
express
two
ligand
monoclon
antibodi
prevent
independ
raav
vector
encod
uniqu
elicit
virusspecif
antibodi
respons
nonoverlap
halv
transgen
overlapupon
secondari
challeng
vector
ping
vector
approach
use
homolog
recombinaposs
combin
block
agent
may
tion
overlap
region
two
independ
provid
complet
abrog
tand
bcell
vector
preliminari
result
seem
indic
immun
respons
transsplic
approach
effi
v
antibodi
neutralis
viru
cient
overlap
approach
reduc
coat
vector
particl
polyethylen
glycol
peg
plasmidbas
deliveri
polyllysin
deaedextran
treatment
ad
advantag
provid
plasmidbas
gene
deliveri
strategi
genermean
retarget
vector
ligand
coupl
alli
regard
safer
less
immunogen
alterto
coat
polym
anoth
potenti
strategi
nativ
viral
vector
repeat
administr
effect
repeat
deliveri
serotyp
switch
lipoplex
mice
cf
patient
result
gene
therapi
initi
one
viru
similar
level
transgen
express
observ
serotyp
switch
viru
deriv
singl
deliveri
thu
suggest
lipoplexsecond
serotyp
subsequ
administr
there
readminist
without
appar
loss
avoid
neutralis
antibodi
induc
efficaci
howev
efficaci
repeat
adminisfirst
serotyp
howev
transgen
express
may
tration
depend
dose
use
time
limit
crossreact
ctl
also
target
interv
administr
lee
et
al
report
cell
infect
second
viru
serotyp
littl
loss
efficaci
observ
use
strategi
combin
provid
dose
lipoplex
low
adenoviru
vector
devoid
viral
time
interv
success
instil
sequenc
gutless
helperdepend
adenovir
suffici
long
appear
inflammavector
therebi
avoid
cellmedi
immun
tion
elicit
complex
may
affect
efficaci
respons
might
possibl
repeatedli
deliv
repeat
administr
viru
use
stealth
adenovirus
nonvir
gene
deliveri
agent
inde
could
elimin
requir
system
iminflammatori
toxic
effect
vivo
scheul
et
al
munosuppress
repeat
administr
observ
dosedepend
pulmonari
inflamm
recombin
aav
raav
vector
gener
characteris
infiltr
neutrophil
less
immunogen
airway
beck
et
al
lesser
extent
macrophag
lymphocyt
recent
suggest
aav
evad
immuth
cation
lipid
administ
mous
nolog
surveil
repeatedli
delung
vivo
associ
elev
liver
rabbit
airway
unabl
level
proinflammatori
cytokin
tnftransduc
antigen
present
cell
dendrit
cell
ifng
peak
day
postinstil
howev
possibl
recent
resolv
normal
limit
day
rule
unless
differ
serotyp
histopatholog
analysi
lung
section
form
immunosuppress
use
furthermic
treat
individu
compon
small
packag
size
limit
virion
lipoplex
suggest
cation
lipid
restrict
use
genet
control
element
major
mediat
observ
inflamm
howdriv
cftr
express
compar
rel
ever
result
clinic
studi
cf
patient
weak
promot
activ
nativ
viral
invert
subject
either
aerosolis
liposom
alon
termin
repeat
itr
sequenc
recent
progress
cation
lipidpdna
complex
indic
overcom
problem
includ
use
bacteri
deriv
pdna
may
also
inflammatori
cation
lipidpdn
scaria
et
al
show
use
adenoviru
treat
patient
liposometr
concoexpress
human
cftr
gene
trol
exhibit
mild
flulik
symptom
includ
shown
block
transport
associ
mhc
fever
myalgia
reduct
fev
approxiclass
imedi
antigen
present
mate
period
h
cell
prolong
express
day
one
possibl
explan
respons
may
observ
monkey
lung
even
though
natur
killer
relat
presenc
unmethyl
cpg
dicel
activ
enhanc
nucleotid
sequenc
bacteri
deriv
pdna
howev
sever
line
evid
suggest
compar
dna
eukaryot
origin
bacteri
attenu
promot
function
may
genom
dna
contain
higher
frequenc
signific
factor
lack
persist
transof
dinucleotid
sequenc
cpg
unlik
gene
express
transcript
activ
eukaryot
dna
approxim
wide
use
cytomegaloviru
immedi
earli
gene
cytosin
methyl
bacteri
dna
rel
promot
cmv
highli
robust
prone
unmethyl
instil
bacteri
dna
oligoinactiv
time
cytokin
induc
adenonucleotid
contain
immunostimulatori
cpg
virusor
plasmidmedi
gene
deliveri
motif
mous
lung
result
inflamm
shown
downregul
cmvdriven
express
lower
respiratori
tract
sever
strategi
reason
mani
investig
evalu
alterhav
employ
decreas
immunon
promot
mani
show
increas
stimulatori
properti
pdna
includ
methpersist
includ
polyubiquitin
c
proylat
cpg
sequenc
ii
reduct
moter
highlevel
transgen
express
cpg
frequenc
elimin
nonessenti
region
week
still
detect
month
sitedirect
mutagenesi
iii
elong
factor
promot
express
use
inhibitor
cpg
signal
pathway
week
cmvubiquitin
b
hybrid
chloroquin
quinacrin
independ
promot
express
month
strategi
use
cpgreduc
pdna
day
level
remain
day
similar
found
less
proinflammatori
howev
methprolong
transgen
express
obtain
ylation
cpg
motif
sever
reduc
region
adenoviru
simpli
open
express
transgen
read
frame
clone
upstream
cmv
promot
plasmid
backbon
howev
potenti
disadvantag
approach
express
therapeut
gene
immunogen
product
express
transfect
cell
therebi
limit
one
main
obstacl
develop
use
vivo
addit
grow
gene
therapi
airway
inabl
evid
genom
sequenc
either
within
current
viral
nonvir
gene
transfer
vector
flank
gene
might
essenti
provid
direct
sustain
express
therapeut
transvivo
longterm
express
gene
may
due
sever
caus
includ
altern
approach
achiev
prolong
loss
vector
especi
present
episomtransgen
express
use
artifici
chromosom
al
form
transcript
silenc
transgen
vector
integr
virus
sinc
stabl
promot
loss
transfect
cell
cell
time
propag
daughter
cell
turnov
gener
immun
respons
cell
divis
occur
huerta
et
al
recent
transgen
product
transfect
cell
develop
circular
yeast
artifici
chromosom
sever
approach
therefor
taken
yac
carri
human
cftr
sequenc
achiev
longerterm
express
follow
gene
orip
gene
epsteinbarr
ebv
transfer
treatment
outlin
section
imviru
plasmid
carri
two
ebv
gene
munosuppress
drug
report
shown
allow
longterm
episom
prolong
transgen
express
mainten
dna
abl
replic
abil
block
cellmedi
respons
addisegreg
daughter
cell
howev
unless
lungresid
stem
cell
target
vector
integr
host
genom
eventu
lost
unlik
greater
advantag
convendu
cell
turnov
tional
plasmid
sinc
airway
epithelium
altern
would
target
lung
resid
mainli
compos
nondivid
cell
furthermor
stem
cell
integr
transgen
continutheir
size
make
vivo
deliveri
subsequ
ousli
propag
daughter
cell
cell
nuclear
traffick
quit
difficult
divis
occur
longstand
regard
integr
virus
aav
debat
regard
ident
airway
epitheli
recent
lentivirus
consid
good
stem
cell
two
theoret
model
cell
lineag
candid
prolong
express
wildtyp
aav
pseudostratifi
airway
epithelium
persist
sitespecif
integr
human
chrosuggest
stem
cell
nich
model
suggest
mosom
howev
recombin
aav
persist
airway
epitheli
stem
cell
localis
distinct
predominantli
episom
form
integr
potenti
inaccess
compart
randomli
host
genom
much
lower
lung
howev
evid
great
plastic
frequenc
wildtyp
aav
probabl
growth
differenti
potenti
airway
lack
rep
gene
product
furthermor
epitheli
cell
earlier
studi
show
result
demonstr
least
liver
extrabas
nonbas
cell
could
regener
comchromosom
integr
genom
priplet
mucociliari
epithelium
tracheal
graft
mari
sourc
raavmedi
gene
express
observ
led
altern
unlimit
plastici
ty
model
mani
nontermin
cell
ampl
lentivir
vector
differ
strain
includ
progenitori
capac
scatter
throughout
human
felin
equin
immunodefici
viru
epithelium
better
understand
issu
use
transduc
airway
epitheli
cell
also
like
benefit
gene
therapi
strategi
potenti
provid
longterm
use
integr
vector
consid
differ
express
integr
proviru
access
stem
cell
two
model
host
cell
genom
kobing
et
al
recent
use
hivbas
vector
pseudotyp
envelop
ebola
eboz
viru
effici
mani
cell
transduc
airway
epithelia
vivo
anim
receiv
correct
achiev
clinic
benefit
ebozpseudotyp
hiv
vector
demonstr
minim
express
day
strong
express
key
issu
distinguish
two
conairway
epithelium
includ
submucos
gland
cept
percent
cell
correct
level
cftr
day
persist
day
averag
transduc
cell
entir
tracheal
epithelium
transduc
vector
day
day
percent
cell
correct
despit
result
integr
vector
still
problem
first
chromosom
posian
vitro
studi
shown
approxim
tion
structur
neg
affect
transgen
correct
cell
need
restor
express
thu
lead
host
shutoff
normal
cl
transport
function
transfer
express
cassett
problem
tion
function
correct
reflect
fact
cl
plagu
retroviru
gene
transfer
vector
effect
move
via
gap
junction
noncorrect
cell
known
transcript
silenc
mitig
adjac
correct
cell
secret
vivo
use
chromatin
insul
studi
shown
normal
level
cftr
proteinbind
dna
element
lack
intrins
gene
express
correct
chlorid
abnorm
promot
enhanc
activ
shelter
gene
normal
importantli
intestin
transcript
influenc
surround
chromatin
patholog
seen
mice
cf
howev
second
problem
major
differ
level
correct
may
requir
epithelium
compris
differenti
cell
restor
variou
function
cftr
relationar
replac
everi
month
transgen
ship
effici
gene
transfer
normalis
sodium
transport
like
linear
gene
use
drive
cftr
express
reflect
fact
cftr
directli
regul
enac
produc
physiolog
cftr
express
channel
within
individu
cell
suggest
approach
use
genom
virtual
everi
affect
cell
corcontext
vector
cftr
express
driven
rect
level
transfect
requir
natur
promot
regulatori
sequenc
function
cftr
restor
eg
sulpha
ii
gene
target
molecul
rnadna
tion
sialyl
defect
transport
molechimer
oligo
small
dna
fragment
cule
remain
unknown
appear
depend
homolog
replac
may
need
latter
cell
type
transduc
gta
use
zhang
et
strategi
would
allow
mutat
within
cftr
al
show
cation
liposomemedi
cftr
gene
surgic
modifi
without
alter
transfer
achiev
low
transgen
express
promot
regulatori
sequenc
cftr
insignific
correct
chlorid
defect
gene
mucu
sulphat
reduc
level
seen
noncf
airway
convers
seen
adenoviru
despit
higher
level
express
nonconvent
approach
transduc
goblet
cell
addit
rout
administr
seem
role
regard
hurdl
encount
gta
localis
deliv
gene
instil
get
airway
epitheli
cell
mani
less
conof
gta
mous
lung
result
predominantli
vention
strategi
describ
transfect
alveolar
termin
bronchial
develop
review
cell
aerosolis
higher
level
transfect
observ
airway
epithelium
oligonucleotidemedi
strategi
aerosolis
like
lead
even
deposit
gta
throughout
lung
size
oligonucleotid
could
attain
instil
prepotenti
enter
cell
nucleu
much
sumabl
primarili
deposit
complex
easili
plasmid
dna
goncz
et
al
deparenchyma
velop
new
strategi
base
gene
target
small
fragment
homolog
replac
sfhr
specif
genom
sequenc
target
small
fragment
exogen
dna
bp
deliv
gene
would
ideal
express
homolog
target
endogen
dna
semann
similar
normal
pattern
defect
quenc
except
particular
base
pair
gene
replac
counterbal
poor
encod
desir
modif
gene
target
gene
transfer
effici
current
gta
thought
sever
advantag
classic
gene
strong
nonspecif
viral
promot
rsv
complement
includ
longterm
tissu
cmv
use
drive
transgen
express
specif
express
function
gene
introhowev
number
cftr
molecul
duction
foreign
sequenc
immun
reper
respiratori
epitheli
cell
low
channel
spons
first
time
goncz
et
al
show
protein
cell
cftr
protein
regul
modif
specif
genom
sequenc
exon
ionic
channel
implic
water
salt
mous
cftr
small
dna
fragment
secret
possibl
high
level
cftr
deliv
lung
normal
mice
express
may
perturb
function
protein
recent
convers
wildtyp
cftr
alter
physiolog
properti
cell
mutat
primari
rat
hepatocyt
report
high
level
cftr
express
report
use
differ
molecul
rnadna
caus
growth
arrest
increas
cell
volum
chimeraplast
thu
suggest
either
regulat
anoth
strategi
use
oligonucleotid
express
cassett
epitheliumspecif
antisens
molecul
friedman
et
al
use
antisens
promot
human
cytokeratin
oligoribonucleotid
correct
cftr
splice
mutat
kb
c
human
mous
uptak
feasibl
method
epitheli
cell
anoth
report
antisens
organand
tissuespecif
lung
repres
inhibit
b
cell
antigen
receptorassoci
proa
challeng
mani
unknown
aspect
gerst
activ
cl
current
dphe
cftrexpress
fect
plasmid
dna
mix
superparamagcho
cell
antisens
strategi
might
suggest
netic
nanoparticl
magnetofect
result
new
way
correct
defect
present
cf
increas
gene
transfer
mucin
product
sodium
hyperabsorpt
challeng
see
whether
promis
techniqu
appli
airway
spliceosomemedi
rna
transsplic
thelium
vivo
smart
utero
gene
transfer
recent
technolog
develop
mitchel
collabor
take
advantag
cell
hurdl
barrier
involv
endogen
splice
machineri
strategi
convent
gene
transfer
sever
group
modifi
premrna
smart
process
use
begun
look
utero
gene
deliveri
new
pretherapeut
rna
molecul
ptm
way
potenti
increas
efficaci
durat
design
base
pair
intron
target
transgen
express
cf
particularli
invit
premrna
suppress
target
cissplic
target
diseas
develop
utero
gene
enhanc
transsplic
ptm
therapi
amniot
fluid
circul
provid
target
aim
repair
mutant
premrna
vector
exposur
pulmonari
gastrointestin
molecul
gener
full
length
repair
mrna
sinu
epithelia
primari
site
cf
patholog
translat
process
matur
cftr
viral
vector
introduc
amniot
fluid
mice
protein
vivo
model
cf
rat
sheep
rabbit
result
report
gene
airway
epithelia
liu
et
al
show
human
cf
express
pulmonari
gastrointestin
bronchial
xenograft
infect
recombin
epithelia
transgen
express
also
demonadenoviru
encod
ptm
target
cftr
intron
strate
pulmonari
epithelia
intratrach
demonstr
partial
correct
cftrmediat
instil
vector
utero
persist
cl
permeabl
seen
noncf
gene
express
lung
rang
xenograft
strategi
would
allow
day
postinfect
studi
physiolog
express
cftr
previous
carri
adenovir
vector
mani
discuss
furthermor
ptm
express
cassett
led
substanti
inflamm
subsequ
foetal
much
smaller
encod
fulllength
loss
fewer
advers
event
observ
cdna
smart
also
allow
use
smaller
aav
use
retrovir
vector
use
applic
less
immunogen
vector
raav
utero
limit
amniot
fluid
limit
packag
capac
howev
high
reduc
infect
see
ref
extend
titr
requir
achiev
correct
potenti
overview
transsplic
noncftr
mrna
di
potenti
advantag
utero
gene
transfer
advantag
ignor
approach
host
immun
system
fulli
develop
may
possibl
physic
method
toleris
organ
viral
vector
howev
recent
report
rule
possibl
ineffici
current
avail
success
repeat
administr
viral
vector
gta
newer
way
increas
gene
transfer
adult
life
despit
previou
utero
exposur
develop
physic
method
magnet
human
approach
would
even
less
ism
electropor
ultrasound
emsuccess
sinc
immun
system
becom
responploy
sever
group
mean
enhanc
gene
sive
midgest
larson
et
al
recent
present
interest
futur
feasibl
option
detect
gene
express
controversi
report
show
treatment
noninvas
way
human
airway
primat
foetus
adenoviru
express
cftr
gene
result
acceler
differenti
lung
furthermor
utero
gene
transfer
conclus
adenoviru
contain
cftr
gene
perman
revers
lethal
phenotyp
cf
conclus
year
sinc
clone
knockout
mice
observ
might
cftr
gene
clinic
trial
suggest
cf
development
diseas
could
crucial
barrier
limit
gene
transfer
prevent
transient
utero
cftr
gene
expreshav
becom
clearer
combin
newli
sion
proper
time
lung
intestin
differendevelop
gta
technolog
better
model
tiation
test
genebas
therapi
new
detect
system
hope
allow
barrier
overcom
clinic
trial
shown
clearli
work
support
cystic
fibrosi
requir
newer
approach
improv
delivresearch
trust
sf
wellcom
trust
senior
eri
effici
increas
durat
express
clinic
fellowship
ewfwa
author
permit
repeat
administr
gta
member
uk
cystic
fibrosi
gene
therapi
addit
increas
need
scientif
consortium
wwwcfgenetherapyorguk
commun
new
gta
technolog
test
relev
airway
test
system
ie
highli
differenti
epitheli
cell
r
efer
vitro
spectrum
vivo
system
enter
clinic
trial
cf
mice
great
